In biotech, most negotiations are won or lost long before the first offer is made.
After 25+ years as a founder, pharma exec, and investor, I’ve learned this:
The real work isn’t at the table – it’s before you even sit down.
- Whether it’s licensing, fundraising, M&A, or market access – great negotiations outcomes hinge on:
- Internal alignment
- Early preparation and planning of the people, process, and substantive dimensions
- Framing the deal in a way that creates mutual value
Too often, teams go in with brilliant science but no clear fallback plan. Or with legal driving the process while BD is unsure of the narrative.
At Crowlight, we help teams prepare for these critical moments – not just tactically, but strategically.
Because in biotech, the stakes are too high to improvise.
Curious how we support founders, investors, and BD leaders before they negotiate?
Let’s talk – or feel free to share this with someone preparing for a big deal.